No Data
No Data
Investors Appear Satisfied With Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Prospects As Shares Rocket 34%
Private Companies Invested in Betta Pharmaceuticals Co., Ltd. (SZSE:300558) Copped the Brunt of Last Week's CN¥1.7b Market Cap Decline
Betta Pharmaceuticals (300558.SZ): CFT8919 capsules have obtained the clinical trial approval notification.
On September 19, Gelonhui reported that Betta Pharmaceuticals (300558.SZ) announced today that Betta Pharmaceuticals Co., Ltd. has received the Drug Clinical Trial Approval Notice (Notice No .: 2024LP02116, 2024LP02117) issued by the National Medical Products Administration (NMPA). The company introduced the CFT8919 capsule from C4 Therapeutics, Inc. (NASDAQ: CCCC) intended for non-small cell lung cancer carrying epidermal growth factor receptor (EGFR) mutation.
Betta Pharmaceuticals (300558.SZ): Intends to sign a regional distribution agreement for pharmaceuticals with He Yuan Biology for the exclusive distribution of plant-derived recombinant human serum albumin injection.
On September 19, Gelonhui announced that on September 19, 2024, Betta Pharmaceuticals Co., Ltd. plans to sign a "He Yuan Biological Medicine Regional Distribution Agreement" with Wuhan Heyuan Biological Technology Co., Ltd. (hereinafter referred to as "Heyuan Biological"). The agreement stipulates the commercial cooperation matters between the two parties regarding the plant-derived recombinant human serum albumin injection (trade name: Aofumin, OsrHSA, HY1001, hereinafter referred to as "plant-derived recombinant human serum albumin injection" or "HY1001"), and the specific total transaction price is based on the actual amount of orders under this agreement.
Betta Pharmaceuticals (300558.SZ): Senior Vice President and Chief Scientist JIABING WANG resigns.
Betta Pharmaceuticals (300558.SZ) announced that the board of directors of the company recently received a resignation letter from a director and senior vice president as well as chief scientist...
Betta Pharmaceuticals (300558.SZ): The clinical trial application for injectable MCLA-129 drug has been accepted.
On September 10th, Betta Pharmaceuticals (300558.SZ) announced that the company's clinical trial application for injection MCLA-129 has received the "Acceptance Notice" (Acceptance No.: CXSL2400603) issued by the National Medical Products Administration (NMPA). The indication for this application is intended for "advanced solid tumors (including but not limited to wild-type colorectal cancer, liver cancer, head and neck squamous cell carcinoma, pancreatic cancer, primary unknown adenocarcinoma, and squamous cell carcinoma and other advanced solid tumors)".
No Data
No Data